Class Action Filed Against Capricor Therapeutics, Inc. (CAPR) Seeking Recovery for Investors - Contact The Gross Law Firm

Core Viewpoint - Capricor Therapeutics, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding its lead cell therapy candidate, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Capricor provided investors with overly positive information about its ability to obtain a Biologics License Application (BLA) from the FDA while concealing adverse facts about the safety and efficacy data from its Phase 2 HOPE-2 trial [1]. - On July 11, 2025, Capricor announced it received a Complete Response Letter (CRL) from the FDA, denying the BLA due to insufficient evidence of effectiveness and the need for additional clinical data, leading to a stock price drop from $11.40 to $7.64 per share [1]. Group 2: Class Action Details - Shareholders who purchased shares during the class period from October 9, 2024, to July 10, 2025, are encouraged to register for the class action, with a deadline of September 15, 2025, to seek lead plaintiff status [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle, with no cost or obligation to participate [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [3].